Research Article
Role of Pretreatment Hemoglobin-to-Platelet Ratio in Predicting Survival Outcome of Locally Advanced Nasopharyngeal Carcinoma Patients
Table 1
Baseline characteristics of the patients in the study.
| Variable | Total () |
| Age, year (mean, SD) | 45.6 (12.2) | Age group, (%) | | ≥60 | 35 (12.11) | <60 | 254 (87.99) | Gender, (%) | | Male | 204 (70.59) | Female | 85 (29.41) | Weight loss, (%) | | 0–5 kg | 221 (76.47) | 5–10 kg | 43 (14.88) | >10 kg | 25 (8.65) | Smoking history, (%) | | Yes | 138 (47.75) | No | 151 (52.25) | ECOG performance scale, (%) | | 0 | 40 (13.84) | 1 | 238 (82.35) | 2 | 11 (3.81) | WHO histopathologic grade, (%) | | 1 | 2 (0.69) | 2 | 14 (4.84) | 2–3 | 9 (3.11) | 3 | 261 (90.31) | Unknown | 3 (1.04) | Clinical stage, (%) | | III | 45(15.57) | IVA | 156 (53.98) | IVB | 88 (30.45) | T, (%) | | T1-T3 | 74 (25.61) | T4 | 215 (74.39) | N, (%) | | N0 | 25 (8.65) | N1 | 44 (15.22) | N2 | 131 (45.33) | N3a | 131 (45.33) | N3b | 64 (22.15) | Therapy, (%) | 25 (8.65) | CCRT | 201 (69.55) | NAC+CCRT | 82 (28.37) | RT | 6 (2.08) | RT cycle (fraction (median, min-max)) | 35 (15-39) | Total dose (Gy (median, min-max)) | 70 (30-78) | Overall time (days (median, min-max)) | 52 (23-97) | Chemosensitizer, (%) | | <5 cycles | 104 (35.99) | ≥5 cycles | 185 (64.01) | RT technique, (%) | | 2D/3DRCT | 168 (58.13) | 2D/3DRCT+IMRT | 14 (4.84) | IMRT | 104 (37.02) | Hemoglobin (g/l (median, min-max)) | 129 (68-167) | Platelet (×103/μl (median, min-max)) | 338 (113-801) | Transfusion on CCRT, (%) | | Yes | 124 (42.91) | No | 165 (57.09) | 3-year mortality, (%) | | Yes | 116 (40.14%) | No | 149 (51.56%) | Lost to follow-up | 24 (8.3%) |
|
|
Notes: 2D: two dimensional; 3D-CRT: three-dimensional-conformal radiotherapy; CCRT: concurrent chemoradiotherapy; ECOG: Eastern Cooperative Oncology Group; IMRT: intensity-modulated radiotherapy; NAC: neoadjuvant chemotherapy; RT: radiotherapy; WHO: World Health Organization.
|